John Mendlein Net Worth

The estimated Net Worth of John Mendlein is at least $1.48 Milhão dollars as of 19 January 2023. John Mendlein owns over 28,461 units of Fate Therapeutics Inc stock worth over $1,207,576 and over the last 11 years he sold FATE stock worth over $31,086. In addition, he makes $245,983 as Independent Vice Chairman of the Board at Fate Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Mendlein FATE stock SEC Form 4 insiders trading

John has made over 5 trades of the Fate Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 28,461 units of FATE stock worth $38,992 on 19 January 2023.

The largest trade he's ever made was buying 124,679 units of Fate Therapeutics Inc stock on 11 January 2023 worth over $698,202. On average, John trades about 10,670 units every 179 days since 2013. As of 19 January 2023 he still owns at least 311,231 units of Fate Therapeutics Inc stock.

You can see the complete history of John Mendlein stock trades at the bottom of the page.

John Mendlein biography

Dr. John D. Mendlein Ph.D. is the Independent Vice Chairman of the Board of Fate Therapeutics, Inc. Dr. Mendlein has served as an Executive Partner of Flagship Pioneering, a venture capital firm, since February 2019. Prior to that, Dr. Mendlein served as President, Corporate and Product Strategy, of Moderna, Inc. (formerly known as Moderna Therapeutics, Inc.), a clinical stage biotechnology company, from January 2018 to February 2019. He also previously served as our Chief Executive Officer, as well as the founding Chairman of the Board and Chief Science Officer. Dr. Mendlein also served as a member of the board of aTyr Pharma, Inc., a biopharmaceutical company, from July 2010 to June 2019, as Executive Chairman of its Board of Directors from July 2010 to December 2015 and as its Chief Executive Officer from September 2011 to November 2017. He also holds board positions with The BIO (Biotechnology Industry Organization) emerging companies board and Editas Medicine, Inc., a genome editing company. Dr. Mendlein previously served from 2005 to 2008 as the Chief Executive Officer of Adnexus Therapeutics, Inc., a biopharmaceutical company, which was purchased by Bristol-Myers Squibb (BMY) in 2008. Dr. Mendlein also served on the board of directors of Monogram Biosciences, Inc., an HIV and oncology diagnostic company that was acquired by Laboratory Corporation of America Holdings in 2009. Before that, he served as Chairman and Chief Executive Officer of Affinium Pharmaceuticals Ltd. (acquired by Debiopharm Group) from 2000 to 2005, and board member, General Counsel and Chief Knowledge Officer at Aurora Bioscience Corporation (acquired by Vertex Pharmaceuticals, Inc.) from August 1996 to September 2001. Dr. Mendlein holds a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in biology from the University of Miami. The Board of Directors has determined that Dr. Mendlein’s extensive business and leadership e

What is the salary of John Mendlein?

As the Independent Vice Chairman of the Board of Fate Therapeutics Inc, the total compensation of John Mendlein at Fate Therapeutics Inc is $245,983. There are 11 executives at Fate Therapeutics Inc getting paid more, with John Wolchko having the highest compensation of $10,721,000.

How old is John Mendlein?

John Mendlein is 60, he's been the Independent Vice Chairman of the Board of Fate Therapeutics Inc since 2017. There are 2 older and 14 younger executives at Fate Therapeutics Inc. The oldest executive at Fate Therapeutics Inc is William Rastetter, 72, who is the Independent Chairman of the Board.

What's John Mendlein's mailing address?

John's mailing address filed with the SEC is C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131.

Insiders trading at Fate Therapeutics Inc

Over the last 11 years, insiders at Fate Therapeutics Inc have traded over $48,476,146 worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth $162,421,037 . The most active insiders traders include Group, Llc Green Jeremy Red..., Associates V Lpvenrock Part..., eAmir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $384,496. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth $2,678.

What does Fate Therapeutics Inc do?

fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade"​ ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.

Complete history of John Mendlein stock trades at Atyr Pharma Inc, Editas Medicine Inc, eFate Therapeutics Inc

Fate Therapeutics Inc executives and stock owners

Fate Therapeutics Inc executives and other stock owners filed with the SEC include:

• John Wolchko,
  President, Chief Executive Officer, Director
• Bahram Valamehr,
  Chief Development Officer
• Cindy Tahl,
  General Counsel and Corporate Secretary
• Daniel Shoemaker,
  Chief Scientific Officer
• J. Scott Wolchko,
  Founder, CEO, Pres & Director
• Dr. Bahram Valamehr Ph.D.,
  Chief R&D Officer
• Cindy R. Tahl,
  Gen. Counsel & Corp. Sec.
• Karin Jooss,
  Independent Director
• Shefali Agarwal,
  Director
• William Rastetter,
  Independent Chairman of the Board
• Timothy Coughlin,
  Independent Director
• John Mendlein,
  Independent Vice Chairman of the Board
• Robert Epstein,
  Independent Director
• Michael Lee,
  Independent Director
• Edward Dulac,
  Chief Financial Officer
• Robert Hershberg,
  Director
• Renee Leck,
  IR Contact Officer
• Yu-Waye Chu,
  Vice President - Clinical Development
• Sarah Cooley,
  Senior Vice President - Clinical Translation
• Dr. Mark Plavsic D.V.M., Ph.D.,
  Chief Technical Officer
• Dr. Yu-Waye Chu M.D.,
  Sr. VP of Clinical Devel.
• Jim Beitel M.B.A.,
  Sr. VP of Corp. Devel.
• Dr. Wen Bo Wang,
  Sr. VP of Technical Operations
• Edward J. Dulac III,
  CFO & Principal Accounting Officer
• Mark J Enyedy,
  Director
• Stewart Abbot,
  Chief Development Officer
• Chris Storgard,
  Chief Medical Officer
• Amir Nashat,
  Director
• Brian T. Powl,
  Chief Commercial Officer
• J Scott Wolchko,
  President and CEO
• Group, Llc Green Jeremy Red...,
  
• Pratik S Multani,
  Chief Medical Officer
• Peter D Flynn,
  See remarks
• Christian Weyer,
  See remarks
• Venture Fund Vi Lparch Vent...,
  
• Venture Partners Vii Lpovp ...,
  
• Venture Management Co. V, L...,
  
• Robert Nelsen,
  Director
• Associates V Lpvenrock Part...,
  
• Yuan Xu,
  
• Mark Plavsic,
  Chief Technical Officer
• Neelufar Mozaffarian,